BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 59 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $72,401 | +1.0% | 73,000 | 0.0% | 0.00% | – |
Q1 2024 | $71,679 | -0.4% | 73,000 | 0.0% | 0.00% | – |
Q4 2023 | $71,949 | +1.6% | 73,000 | 0.0% | 0.00% | – |
Q3 2023 | $70,810 | -1.2% | 73,000 | 0.0% | 0.00% | – |
Q2 2023 | $71,706 | -4.3% | 73,000 | 0.0% | 0.00% | – |
Q1 2023 | $74,897 | -3.3% | 73,000 | 0.0% | 0.00% | – |
Q4 2022 | $77,475 | +7.6% | 73,000 | 0.0% | 0.00% | – |
Q3 2022 | $72,000 | 0.0% | 73,000 | 0.0% | 0.00% | – |
Q2 2022 | $72,000 | – | 73,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |
LOOMIS SAYLES & CO L P | 901,591 | $69,512,000 | 0.09% |